ARANESP -(HSA-FREE) 200 MCG — DIN 02246358
DARBEPOETIN ALFA : 200 MCG · AMGEN CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ARANESP -(HSA-FREE)?
ARANESP -(HSA-FREE) 200 MCG contains DARBEPOETIN ALFA : 200 MCG. It is listed in the Health Canada Drug Product Database under DIN 02246358, held by AMGEN CANADA INC, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 04-Aug-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ARANESP -(HSA-FREE) used for?
Anemia associated with chronic kidney disease (CKD) in patients on or not on dialysis. Anemia due to chemotherapy in patients with non-myeloid malignancies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Darbepoetin Alfa cost around the world?
Darbepoetin Alfa is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Australia | ex-manufacturer | 2 | 30 |
| Norway | max AUP (pharmacy retail) | 1 | 22 |
| Austria | KVP (Kassenverkaufspreis) | 18 | 18 |
| Czechia | max producer price (ex-factory) | 1 | 17 |
| Greece | producer price (ex-factory) | 17 | 17 |
| Hungary | producer price (ex-factory) | 13 | 17 |
| Luxembourg | reimbursement | 14 | 14 |
| Saudi Arabia | public | 12 | 12 |
| Bahrain | retail (max) | 2 | 11 |
| United Arab Emirates | public | 6 | 6 |
| South Africa | single exit price | 5 | 5 |
169 pack listings across 91 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Darbepoetin Alfa pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Darbepoetin Alfa in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Darbepoetin Alfa — 24 DINs, of which 13 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AMGEN CANADA INC | 24 | 13 | ARANESP, ARANESP -(HSA-FREE) | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MCG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS ; SUBCUTANEOUS |
| Pack configuration (monograph) | Single-use vials (15-500 mcg) and SingleJect prefilled syringes (10-500 mcg). Note: Vials and certain syringe strengths (15, 250, 400 mcg) not available in Canada. |
| Storage | Not explicitly detailed in the provided text snippet (refer to STORAGE AND STABILITY section 27). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Darbepoetin Alfa |
|---|---|
| ATC code | B03XA02 |
| AHFS class | 20:16.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02246358 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2246358 |
| Brand name | ARANESP -(HSA-FREE) |
| Generic / active ingredient | DARBEPOETIN ALFA : 200 MCG |
| Market authorization holder | AMGEN CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | B03XA02 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B03XA |
| Current status | CANCELLED POST MARKET |
| Status date | 04-Aug-2015 |
| Original market date | 2002-08-13 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
CKD: SC or IV. Individualize to maintain Hb 100-120 g/L. Cancer: SC only. Use lowest dose to avoid RBC transfusion. Rate of Hb rise should not exceed 10 g/L in any 2-week period.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Uncontrolled hypertension; Pure Red Cell Aplasia (PRCA) following ESA treatment; hypersensitivity to darbepoetin alfa, excipients, or mammalian cell-derived products; sensitivity to albumin.
Warnings and precautions
Increased risk of death, serious CV events, and stroke if Hb >130 g/L (CKD) or >120 g/L (Cancer). Risk of tumor progression in cancer patients. PRCA and serious allergic reactions reported.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
13 of 24 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARANESP | 500 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391805 |
| ARANESP | 25 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02392313 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391783 |
| ARANESP | 500 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391791 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391775 |
| ARANESP | 300MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391821 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391767 |
| ARANESP | 100 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391740 |
| ARANESP | 100 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02391759 |
| ARANESP | 40 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | 02392321 |
2 · Same class — other molecules in ATC B03XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Darbepoetin Alfa | ARANESP · ARANESP -(HSA-FREE) | 24 | 13 | Yes |
| Erythropoietin | EPREX STERILE SOLUTION · EPREX STERILE SOLUTION 10000IU/1.0ML · EPREX STERILE SOLUTION 10000IU/ML · EPREX STERILE SOLUTION 1000IU/0.5ML · +10 more | 15 | 11 | Yes |
| Luspatercept | REBLOZYL | 2 | 2 | Yes |
| Methoxy Polyethylene Glycol-Epoetin Beta | MIRCERA | 15 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ARANESP -(HSA-FREE) called?
The same molecule, Darbepoetin Alfa, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Aranesp | Latin | Australia, Bahrain, Czechia, Norway |
| Aranesp SureClick | Latin | Australia |
| ARANESP WITH ANG | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.